ReviewClinical microbiology reviews1996
Immunopathogenesis of recurrent vulvovaginal candidiasis.
Review in Clinical microbiology reviews, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 295 citations in OpenAlex.
- An IL-1, IL-17, and IL-22 cytokine circuit controls vulvovaginal candidiasis independently of estrogen.PLoS pathogens · 2026Article
- The interventional value and research progress of vaginal microbiota transplantation in improving female sexual quality of life associated with dysbiosis of the reproductive microecosystem.Frontiers in medicine · 2026Review
- Article
- Vaginal mycobiome characteristics and therapeutic strategies in vulvovaginal candidiasis (VVC): differentiating pathogenic species and microecological features for stratified treatment.Clinical microbiology reviews · 2025Review
- The Interplay betweenMicroorganisms · 2023Review
- Polyphyllin I EffectsEvidence-based complementary and alternative medicine : eCAM · 2023Article
- Biased Genotype Distributions of Candida albicans Strains Associated with 649 Clinical Vulvovaginal Candidiasis in China.Mycopathologia · 2022Article
- Role of Vaginal Mucosa, Host Immunity and Microbiota in Vulvovaginal Candidiasis.Pathogens (Basel, Switzerland) · 2022Review
- The Role of IL-17 During Infections in the Female Reproductive Tract.Frontiers in immunology · 2022Review
- Article
- Vulvovaginal Candidosis: Current Concepts, Challenges and Perspectives.Journal of fungi (Basel, Switzerland) · 2020Review
- Psoriasin, a novel anti-Candida albicans adhesin.Journal of molecular medicine (Berlin, Germany) · 2018Article
- Predictors of esophageal candidiasis among patients attending endoscopy unit in a tertiary hospital, Tanzania: a retrospective cross-sectional study.African health sciences · 2018Article
- A pre-therapeutic coating for medical devices that prevents the attachment of Candida albicans.Annals of clinical microbiology and antimicrobials · 2017Article
- The vaginal mycobiome: A contemporary perspective on fungi in women's health and diseases.Virulence · 2017Review
- In vitro activity of Spirulina platensis water extract against different Candida species isolated from vulvo-vaginal candidiasis cases.PloS one · 2017Article
- Progresses in vaginal microflora physiology and implications for bacterial vaginosis and candidiasis.Women's health (London, England) · 2016Article
- A Murine Model of Candida glabrata Vaginitis Shows No Evidence of an Inflammatory Immunopathogenic Response.PloS one · 2016Article
- The EPA2 adhesin encoding gene is responsive to oxidative stress in the opportunistic fungal pathogen Candida glabrata.Current genetics · 2015Article
- CX3CR1 is dispensable for control of mucosal Candida albicans infections in mice and humans.Infection and immunity · 2015Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent vulvovaginal candidiasis (RVVC) is a prevalent opportunistic mucosal infection, caused predominantly by Candida albicans, which affects a significant number of otherwise healthy women of childbearing age. Since there are no known exogenous predisposing factors to explain the incidence of symptomatic vaginitis in most women with idiopathic RVVC, it has been postulated that these particular women suffer from an immunological abnormality that prediposes them to RVVC. Because of the increased incidence of mucosal candidiasis in individuals with depressed cell-mediated immunity (CMI), defects in CMI are viewed as a possible explanation for RVVC. In this review, we attempt to place into perspective the accumulated information regarding the immunopathogenesis of RVVC, as well as to provide new immunological perspectives and hypotheses regarding potential immunological deficiencies that may predispose to RVVC and potentially other mucosal infections by the same organism. The results of both clinical studies and studies in an animal model of experimental vaginitis suggest that systemic CMI may not be the predominant host defense mechanism against C. albicans vaginal infections. Rather, locally acquired mucosal immunity, distinct from that in the peripheral circulation, is now under consideration as an important host defense at the vaginal mucosa, as well as the notion that changes in local CMI mechanism(s) may predispose to RVVC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.